Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026)
Innoviva's (INVA) quarterly Other Non-Current Liabilities came in at $69.1 million in Q1 2026, up 485.92% YoY from $11.8 million in Q1 2025, and up 21.21% on a QoQ basis from $57.0 million in Q4 2025.
Analysis
Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Innoviva (INVA) has 13 years of Other Non-Current Liabilities data on file, last reported at $69.1 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 485.92% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (up 485.92% YoY) and the FY2025 annual result came in at $57.0 million, down 11.3% from the prior year.
- Other Non-Current Liabilities improved to $69.1 million in Q1 2026, from $57.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $78.4 million in Q3 2022 to a low of $1.1 million in Q3 2024.
- A 5-year average of $58.8 million and a median of $68.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 560050.0% — and 2024, when it slumped 98.43%.
- Tracing INVA's Other Non-Current Liabilities over 5 years: stood at $67.9 million in 2022, then advanced by 5.77% to $71.9 million in 2023, then slipped by 10.57% to $64.3 million in 2024, then retreated by 11.3% to $57.0 million in 2025, then rose by 21.21% to $69.1 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $69.1 million (Q1 2026), $57.0 million (Q4 2025), and $55.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67.28 Mn |
| Mar 31, 2026 | 69.10 Mn |
| Dec 31, 2025 | 66.09 Mn |
| Sep 30, 2025 | 57.43 Mn |
| Jun 30, 2025 | 60.02 Mn |
| Mar 31, 2025 | 62.01 Mn |
| Dec 31, 2024 | 64.28 Mn |
| Sep 30, 2024 | 71.45 Mn |
| Jun 30, 2024 | 72.07 Mn |
| Mar 31, 2024 | 71.69 Mn |
| Dec 31, 2023 | 71.87 Mn |
| Sep 30, 2023 | 68.69 Mn |
| Jun 30, 2023 | 68.58 Mn |
| Mar 31, 2023 | 70.13 Mn |
| Dec 31, 2022 | 70.92 Mn |
| Sep 30, 2022 | 78.42 Mn |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 45,000.00 |
| Mar 31, 2021 | 77,000.00 |
| Dec 31, 2020 | 106,000.00 |